Bevacizumab neutralizes the protective effect of vascular endothelial growth factor on retinal ganglion cells.
Brar
Vikram S
VS
University of Florida College of Medicine, Department of Ophthalmology Jacksonville, FL 32209, USA.
Sharma
Rajesh K
RK
Murthy
Ravi K
RK
Chalam
K V
KV
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D057134:Antibodies, Neutralizing / Q000494:pharmacology*; D000068258:Bevacizumab; D016923:Cell Death / Q000187:drug effects; D002454:Cell Differentiation / Q000187:drug effects; D002460:Cell Line; D048430:Cell Shape / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D019610:Cytoprotection / Q000187:drug effects*; D006801:Humans; D007150:Immunohistochemistry; D018384:Oxidative Stress / Q000187:drug effects; D020011:Protective Agents / Q000494:pharmacology*; D051381:Rats; D012165:Retinal Ganglion Cells / Q000166:cytology* / Q000187:drug effects*; D042461:Vascular Endothelial Growth Factor A / Q000494:pharmacology*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D057134:Antibodies, Neutralizing; D020011:Protective Agents; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab